Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 7
Submit an article Journal homepage
658
Views
40
CrossRef citations to date
0
Altmetric
Review

Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges

Laura L Rokosz Pharmacopeia, Inc., PO Box 5350, Princeton, NJ 08543-5350, USA +1 609 452 3600; +1 609 655 4187; [email protected]
,
James R Beasley Pharmacopeia, Inc., PO Box 5350, Princeton, NJ 08543-5350, USA +1 609 452 3600; +1 609 655 4187; [email protected]
,
Carolyn DiIanni Carroll Pharmacopeia, Inc., PO Box 5350, Princeton, NJ 08543-5350, USA +1 609 452 3600; +1 609 655 4187; [email protected]
,
Tsung Lin Pharmacopeia, Inc., PO Box 5350, Princeton, NJ 08543-5350, USA +1 609 452 3600; +1 609 655 4187; [email protected]
,
Jiuqiao Zhao Pharmacopeia, Inc., PO Box 5350, Princeton, NJ 08543-5350, USA +1 609 452 3600; +1 609 655 4187; [email protected]
,
Kenneth C Appell Pharmacopeia, Inc., PO Box 5350, Princeton, NJ 08543-5350, USA +1 609 452 3600; +1 609 655 4187; [email protected]
&
Maria L Webb Pharmacopeia, Inc., PO Box 5350, Princeton, NJ 08543-5350, USA +1 609 452 3600; +1 609 655 4187; [email protected]
 show all
Pages 883-903 | Published online: 13 Jun 2008

Bibliography

  • Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-30
  • Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83
  • Raingeaud J, Whitmarsh AJ, Barrett T, et al. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 1996;16:1247-55
  • Allen M, Svensson L, Roach M, et al. Deficiency of the stress kinase p38α results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med 2000;191:859-70
  • Adams JL, Badger AM, Kumar S, et al. p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. Prog Med Chem 2001;38:1-60
  • Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46
  • Henry JR, Cavender DE, Wadsworth SA. p38 Mitogen-activated protein kinase as a target for drug discovery. Drugs Future 1999;24:1345-54
  • Salituro FG, Germann UA, Wilson KP, et al. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr Med Chem 1999;6:807-23
  • Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71
  • Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-66
  • Cvetkovic RS, Keating G. Anakinra. BioDrugs 2002;16:303-11
  • Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-26
  • Kumar S, McDonnell PC, Gum RJ, et al. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 1997;235:533-8
  • McLay LM, Halley F, Souness JE, et al. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg Med Chem 2001;9:537-54
  • Natarajan SR, Wisnoski DD, Singh SB, et al. p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold. Bioorg Med Chem Lett 2003;13:273-6
  • Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;9:268-72
  • Wadsworth SA, Cavender DE, Beers SA, et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999;291:680-7
  • Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat Cell Biol 1999;1:94-7
  • Lin TH, Metzger A, Diller DJ, et al. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors. J Pharmacol Exp Ther 2006;318:495-502
  • Godl K, Wissing J, Kurtenbach A, et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 2003;100:15434-9
  • Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36
  • Diller DJ, Lin TH, Metzger A. The discovery of novel chemotypes of p38 kinase inhibitors. Curr Top Med Chem 2005;5:953-65
  • Chen M, Cheng A, Candotti F, et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol 2000;20:947-56
  • Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000;20:3387-95
  • Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995;377:65-8
  • Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995;270:797-800
  • Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-8
  • Kudlacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004;4:51-7
  • Milici AJ, Audoly L, Beckius GE, et al. Cartilage preservation by inhibition of Janus kinase 3 (JAK3) in a murine collagen induced-arthritis (CIA) model and rat adjuvant-arthritis (AA) model. American College of Rheumatology 70th Annual Meeting; 2006; Washington, DC; 2006. Presentation number 789. Availabel from: http://www.abstractsonline.com/viewer/?mkey=%7BC297FAF7%2D2B4C%2D45F5%2DA662%2D0972E559ED7D%7D%20
  • Busque S, Leventhal J, Brennan D, et al. CP-690,550 (CP), a JAK3 inhibitor, in de novo kidney transplant (KT) recipients: 6-month results of a phase 2 trial [abstract 601]. Am J Transpl 2007;7(s2):304
  • Sudbeck EA, Liu XP, Narla RK, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999;5:1569-82
  • Kirken RA, Erwin RA, Taub D, et al. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol 1999;65:891-9
  • Stepkowski SM, Erwin-Cohen RA, Behbod F, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002;99:680-9
  • Stepkowski SM, Kao J, Wang ME, et al. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol 2005;175:4236-46
  • Cortes JR, Perez GM, Rivas MD, et al. Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. J Immunol 2007;179:3881-7
  • Sills M, Appell K, Bohnstedt A, et al. In vitro and in vivo characterization of a novel Jak3 tyrosine kinase inhibitor. Inflamm Res 2006;55:S118
  • Chang B, Zhao F, Lau A, et al. Novel Jak kinase inhibitors reverse inflammation and bone erosion in a collagen-induced arthritis (CIA) treatment model: PK/PD evaluation using phospho-flow cytometry. Program of Keystone Symposia: Jaks, Stats and Immunity; 2007; Steamboat Springs, CO, USA (Abstract 111)
  • Hendry S, Sheikh A, Bogt K, et al. Prevention of acute rejection with a novel Janus kinase 3 (JAK-3) inhibitor in a rodent heterotopic cardiac allograft model. World Transplantation Congress; 2006; Boston, MA USA. Am J Transpl 2006;6(Suppl 2):901
  • Deuse T VJ, Hoyt G, Govaert JA, et al. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation 2008;85:885-92
  • Chan G, Wang C, Boy M, et al. Dose-dependent reduction in psoriasis severity as evidence of immunosuppressive activity of an oral JAK3 inhibitor in humans. Am J Transpl 2006;6(Suppl 2):87
  • Kremer J, Bloom B, Breedveld F. A randomized, double-blind placebo-controlled trial of 3 dose levels of CP-690, 550 versus placebo in the treatment of active rheumatoid arthritis [abstract L40]. American College of Rheumatology 70th Annual Meeting; 2006; Washington, DC
  • Rubins A, Gutmane R, Valdmane N, et al. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol 2005;125:68-71
  • Goodman PA, Wood CM, Vassilev AO, et al. Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia. Leuk Lymphoma 2003;44:1011-8
  • Vassilev AO, Uckun FM. Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK). Curr Pharm Des 2004;10:1757-66
  • Rawlings DJ, Scharenberg AM, Park H, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 1996;271:822-5
  • Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361:226-33
  • Khan WN. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol Res 2001;23:147-56
  • Ohta Y, Haire RN, Litman RT, et al. Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia. Proc Natl Acad Sci USA 1994;91:9062-6
  • Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993;261:358-61
  • Sideras P, Muller S, Shiels H, et al. Genomic organization of mouse and human Bruton's agammaglobulinemia tyrosine kinase (Btk) loci. J Immunol 1994;153:5607-17
  • Lindvall JM, Blomberg KE, Valiaho J, et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 2005;203:200-15
  • Watanabe D, Hashimoto S, Ishiai M, et al. Four tyrosine residues in phospholipase C-γ2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling. J Biol Chem 2001;276:38595-601
  • Uckun FM. Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem Pharmacol 1998;56:683-91
  • Horwood NJ, Mahon T, McDaid JP, et al. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor α production. J Exp Med 2003;197:1603-11
  • Horwood NJ, Page TH, McDaid JP, et al. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol 2006;176:3635-41
  • Mangla A, Khare A, Vineeth V, et al. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood 2004;104:1191-7
  • Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
  • Hata D, Kawakami Y, Inagaki N, et al. Involvement of Bruton's tyrosine kinase in FcϵRI-dependent mast cell degranulation and cytokine production. J Exp Med 1998;187:1235-47
  • Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007;104:13283-8
  • Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem Med Chem 2007;2:58-61
  • Mahajan S, Ghosh S, Sudbeck EA, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem 1999;274:9587-99
  • Uckun FM, Zheng Y, Cetkovic-Cvrlje M, et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res 2002;8:1224-33
  • Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett 2002;527:274-8
  • Cetkovic-Cvrlje M, Uckun FM. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br J Haematol 2004;126:821-7
  • Uckun FM, Vassilev A, Bartell S, et al. The anti-leukemic Bruton's tyrosine kinase inhibitor α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism. Leuk Lymphoma 2003;44:1569-77
  • Kawakami Y, Hartman SE, Kinoshita E, et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. Proc Natl Acad Sci USA 1999;96:2227-32
  • Basu S, Bose SK Jr, Bose SK. Characterization of versilin-sensitive sites in self-sensitive producer and sensitive non-producer or unrelated organism. J Appl Bacteriol 1989;67:191-200
  • Osada S, Mizuno K, Saido TC, et al. A new member of the protein kinase C family, nPKCθ, predominantly expressed in skeletal muscle. Mol Cell Biol 1992;12:3930-8
  • Chang JD, Xu Y, Raychowdhury MK, et al. Molecular cloning and expression of a cDNA encoding a novel isoenzyme of protein kinase C (nPKC). A new member of the nPKC family expressed in skeletal muscle, megakaryoblastic cells, and platelets. J Biol Chem 1993;268:14208-14
  • Hayashi K, Altman A. Protein kinase C theta (PKCθ): a key player in T cell life and death. Pharmacol Res 2007;55:537-44
  • Sedwick CE, Altman A. Perspectives on PKCθ in T cell activation. Mol Immunol 2004;41:675-86
  • Sun Z, Arendt CW, Ellmeier W, et al. PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes. Nature 2000;404:402-7
  • Pfeifhofer C, Kofler K, Gruber T, et al. Protein kinase C θ affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J Exp Med 2003;197:1525-35
  • Anderson K, Fitzgerald M, Dupont M, et al. Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases. Autoimmunity 2006;39:469-78
  • Salek-Ardakani S, So T, Halteman BS, et al. Protein kinase Cθ controls Th1 cells in experimental autoimmune encephalomyelitis. J Immunol 2005;175:7635-41
  • Tan SL. PKCθ: a potential therapeutic target for multiple sclerosis. Presented at the 4th Annual Protein Kinase Targets conference; 2006 June 12 – 14, Boston, MA, USA
  • Healy AM, Izmailova E, Fitzgerald M, et al. PKC-θ-deficient mice are protected from Th1-dependent antigen-induced arthritis. J Immunol 2006;177:1886-93
  • Marsland BJ, Soos TJ, Spath G, et al. Protein kinase C θ is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses. J Exp Med 2004;200:181-9
  • Salek-Ardakani S, So T, Halteman BS, et al. Differential regulation of Th2 and Th1 lung inflammatory responses by protein kinase Cθ. J Immunol 2004;173:6440-7
  • Berg-Brown NN, Gronski MA, Jones RG, et al. PKCθ signals activation versus tolerance in vivo. J Exp Med 2004;199:743-52
  • Giannoni F, Lyon AB, Wareing MD, et al. Protein kinase C θ is not essential for T-cell-mediated clearance of murine gammaherpesvirus 68. J Virol 2005;79:6808-13
  • van Eis MJ. NVP-AEB071: first protein kinase c inhibitor prolonging graft survival in a transplantation model. XIXth International Symposium on Medicinal Chemistry; 2006 August 29 – September 2, Istanbul, Turkey
  • Slade A, Jung T, Hijazi Y, et al. AEB071: safety and activity of a novel T-cell activation inhibitor in psoriasis patients. 2007
  • Cywin CL, Dahmann G, Prokopowicz AS 3rd, et al. Discovery of potent and selective PKC-θ inhibitors. Bioorg Med Chem Lett 2007;17:225-30
  • Leitges M, Plomann M, Standaert ML, et al. Knockout of PKCα enhances insulin signaling through PI3K. Mol Endocrinol 2002;16:847-58
  • Pfeifhofer C, Gruber T, Letschka T, et al. Defective IgG2a/2b class switching in PKC α-/- mice. J Immunol 2006;176:6004-11
  • Mecklenbrauker I, Saijo K, Zheng NY, et al. Protein kinase Cδ controls self-antigen-induced B-cell tolerance. Nature 2002;416:860-5
  • Miyamoto A, Nakayama K, Imaki H, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ. Nature 2002;416:865-9
  • Janssens S, Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 2003;11:293-302
  • Kuglstatter A, Villasenor AG, Shaw D, et al. Cutting Edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations. J Immunol 2007;178:2641-5
  • Wang Z, Liu J, Sudom A, et al. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Structure 2006;14:1835-44
  • Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511
  • O'Neill LA. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 2003;3:396-403
  • Li S, Strelow A, Fontana EJ, et al. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA 2002;99:5567-72
  • Yao J, Kim TW, Qin J, et al. Interleukin-1 (IL-1)-induced TAK1-dependent Versus MEKK3-dependent NFκB activation pathways bifurcate at IL-1 receptor-associated kinase modification. J Biol Chem 2007;282:6075-89
  • Suzuki N, Suzuki S, Duncan GS, et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 2002;416:750-6
  • Qin J, Jiang Z, Qian Y, et al. IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness. J Biol Chem 2004;279:26748-53
  • Lye E, Mirtsos C, Suzuki N, et al. The role of interleukin 1 receptor-associated kinase-4 (IRAK-4) kinase activity in IRAK-4-mediated signaling. J Biol Chem 2004;279:40653-8
  • Kim TW, Staschke K, Bulek K, et al. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J Exp Med 2007;204:1025-36
  • Kawagoe T, Sato S, Jung A, et al. Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling. J Exp Med 2007;204:1013-24
  • Koziczak-Holbro M, Joyce C, Gluck A, et al. IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and toll-like receptor 7-mediated signaling and gene expression. J Biol Chem 2007;282:13552-60
  • Suzuki N, Suzuki S, Millar DG, et al. A critical role for the innate immune signaling molecule IRAK-4 in T cell activation. Science 2006;311:1927-32
  • Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003;299:2076-9
  • Medvedev AE, Lentschat A, Kuhns DB, et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 2003;198:521-31
  • Ku CL, von Bernuth H, Picard C, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007;204:2407-22
  • Smith RJ. Therapies for rheumatoid arthritis: hope springs eternal. Drug Discov Today 2005;10:1598-606
  • Fernandes LB, Henry PJ, Goldie RG. Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis 2007;1:25-33
  • Hu E, Lee D. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. Expert Opin Ther Targets 2005;9:715-36
  • Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98:322-34
  • Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4:387-98
  • Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003;4:446-56
  • Seasholtz TM, Brown JH. Rho signaling in vascular diseases. Mol Interv 2004;4:348-57
  • Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007;28:296-302
  • Xing XQ, Gan Y, Wu SJ, et al. Therapeutic potential of Rho-kinase inhibitors in asthma. Med Hypotheses 2007;68:705-6
  • Chiba Y, Ueno A, Shinozaki K, et al. Involvement of RhoA-mediated Ca2+ sensitization in antigen-induced bronchial smooth muscle hyperresponsiveness in mice. Respir Res 2005;6:4-15
  • Gosens R, Schaafsma D, Grootte Bromhaar MM, et al. Growth factor-induced contraction of human bronchial smooth muscle is Rho-kinase-dependent. Eur J Pharmacol 2004;494:73-6
  • Henry PJ, Mann TS, Goldie RG. A rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice. Pulm Pharmacol Ther 2005;18:67-74
  • Urata Y, Nishimura Y, Hirase T, et al. Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase. Kobe J Med Sci 2005;51:17-27
  • Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 2007;21:167-77
  • Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-4
  • Stavenger R. Rho kinase inhibitors as potential therapeutic agents for cardiovascular disease. Gordon Conference on Medicinal Chemistry; 2007; New London, NH: GlaxoSmithKline
  • Ishikawa Y, Nishikimi T, Akimoto K, et al. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 2006;47:1075-83
  • Nishikimi T, Matsuoka H. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis. J Pharmacol Sci 2006;100:22-8
  • Nakagawa O, Fujisawa K, Ishizaki T, et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996;392:189-93
  • Leung T, Chen XQ, Manser E, et al. The p160 RhoA-binding kinase ROKα is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996;16:5313-27
  • Riento K, Totty N, Villalonga P, et al. RhoE function is regulated by ROCK-I mediated phosphorylation. EMBO J 2005;24:1170-80
  • Shimizu Y, Thumkeo D, Keel J, et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 2005;168:941-53
  • Thumkeo D, Keel J, Ishizaki T, et al. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 2003;23:5043-55
  • Ellis J, Kuo J, McGonigle S, et al. Ability of the ROCK-2 selective inhibitor SLx-2119 to inhibit septic liver injury [abstract FC11.7]. 8th World Congress on Inflammation; 2007 June 16 – 20; Copenhagen Conference Center, Bella Center, Copenhagen, Denmark. Inflamm Res 2007;56(Suppl 3):S403
  • Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 2002;93:225-32
  • Tamura M, Nakao H, Yoshizaki H, et al. Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta 2005;1754:245-52
  • Lindsley C, Zhao Z, Leister W, et al. Allosteric AKT (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 2005;761-4
  • Available from: http://www.scientific.thomson.com
  • Creager MA. The effect of fasudil on vascular function in humans. 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00120718 [Last accessed 10 December 2007]
  • Wigley FD. A rho-kinase inhibitor (Fasudil) in the treatment of Raynaud's phenomenon. 2007. Available from: http://clinicaltrials.gov/show/NCT00498615 [Last accessed 10 December 2007]
  • Mitsubishi Tanabe Pharma pipeline. 2008. Available from: http://www.evaluatepharma.com/CoInfo/CoInfo-TAN.htm [Last accessed 5 May 2008]
  • KOWA Pharmaceuticals pipeline. 2007. Available from: http://www.kowa.co.jp/eng/g/rd/pipeline.htm [Last accessed 5 May 2008]
  • Santen Annual Report 2007. Santen Pharmaceutical Co, Ltd Annual Report 2007. 2007. Available from: http://www.santen.com/ir/reports/ar2007.jsp [Last accessed 5 May 2008]
  • Branca MA, Sannes L. Multi-target kinase inhibitors hitting the market. PharmaWeek. 2006 March 24. Available from: http://www.pharmaweek.com/FlashReport/MultiTarget%20Kinase.asp [Last accessed 9 May 2008]
  • Zheng C, Han L, Yap CW, et al. Progress and problems in the exploration of therapeutic targets. Drug Discov Today 2006;11:412-20

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.